Insmed Incorporated (LON: 0JAV)

Market Cap	11.40B
Revenue (ttm)	255.88M
Net Income (ttm)	-644.84M
Shares Out	n/a
EPS (ttm)	-4.15
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,149
Average Volume	1,038
Open	77.37
Previous Close	76.87
Day's Range	76.97 - 78.48
52-Week Range	16.59 - 78.48
Beta	1.12
RSI	64.69
Earnings Date	Feb 20, 2025

About Insmed

Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil P...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 1988
• Employees: 912
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0JAV

Financial Performance

In 2023, Insmed's revenue was $305.21 million, an increase of 24.39% compared to the previous year's $245.36 million. Losses were -$749.57 million, 55.7% more than in 2022.

Financial numbers in USD